Viatris Receivables 2010-2025 | VTRS
Viatris receivables from 2010 to 2025. Receivables can be defined as the total amount of collectibles for a company
- Viatris receivables for the quarter ending March 31, 2025 were $3.126B, a 13.94% decline year-over-year.
- Viatris receivables for 2024 were $3.221B, a 12.95% decline from 2023.
- Viatris receivables for 2023 were $3.7B, a 2.99% decline from 2022.
- Viatris receivables for 2022 were $3.815B, a 10.59% decline from 2021.
| Viatris Annual Receivables (Millions of US $) |
|
|---|---|
| 2024 | $3,221 |
| 2023 | $3,700 |
| 2022 | $3,815 |
| 2021 | $4,266 |
| 2020 | $4,844 |
| 2019 | $3,059 |
| 2018 | $2,881 |
| 2017 | $3,612 |
| 2016 | $3,311 |
| 2015 | $2,689 |
| 2014 | $2,269 |
| 2013 | $1,820 |
| 2012 | $1,554 |
| 2011 | $1,426 |
| 2010 | $1,157 |
| 2009 | $1,235 |
| Viatris Quarterly Receivables (Millions of US $) |
|
|---|---|
| 2025-03-31 | $3,126 |
| 2024-12-31 | $3,221 |
| 2024-09-30 | $3,717 |
| 2024-06-30 | $3,567 |
| 2024-03-31 | $3,632 |
| 2023-12-31 | $3,700 |
| 2023-09-30 | $3,739 |
| 2023-06-30 | $3,607 |
| 2023-03-31 | $3,498 |
| 2022-12-31 | $3,815 |
| 2022-09-30 | $3,334 |
| 2022-06-30 | $3,736 |
| 2022-03-31 | $4,094 |
| 2021-12-31 | $4,266 |
| 2021-09-30 | $4,346 |
| 2021-06-30 | $4,479 |
| 2021-03-31 | $4,529 |
| 2020-12-31 | $4,844 |
| 2020-09-30 | $2,964 |
| 2020-06-30 | $2,753 |
| 2020-03-31 | $2,775 |
| 2019-12-31 | $3,059 |
| 2019-09-30 | $2,948 |
| 2019-06-30 | $2,704 |
| 2019-03-31 | $2,779 |
| 2018-12-31 | $2,881 |
| 2018-09-30 | $2,949 |
| 2018-06-30 | $2,818 |
| 2018-03-31 | $3,025 |
| 2017-12-31 | $3,612 |
| 2017-09-30 | $3,220 |
| 2017-06-30 | $2,951 |
| 2017-03-31 | $2,872 |
| 2016-12-31 | $3,311 |
| 2016-09-30 | $3,099 |
| 2016-06-30 | $2,917 |
| 2016-03-31 | $2,587 |
| 2015-12-31 | $2,689 |
| 2015-09-30 | $2,917 |
| 2015-06-30 | $2,861 |
| 2015-03-31 | $2,265 |
| 2014-12-31 | $2,269 |
| 2014-09-30 | $1,733 |
| 2014-06-30 | $1,762 |
| 2014-03-31 | $1,679 |
| 2013-12-31 | $1,820 |
| 2013-09-30 | $1,717 |
| 2013-06-30 | $1,651 |
| 2013-03-31 | $1,514 |
| 2012-12-31 | $1,554 |
| 2012-09-30 | $1,500 |
| 2012-06-30 | $1,526 |
| 2012-03-31 | $1,538 |
| 2011-12-31 | $1,426 |
| 2011-09-30 | $1,280 |
| 2011-06-30 | $1,441 |
| 2011-03-31 | $1,336 |
| 2010-12-31 | $1,157 |
| 2010-09-30 | $1,252 |
| 2010-06-30 | $1,249 |
| 2010-03-31 | $1,197 |
| 2009-12-31 | $1,235 |
| 2009-09-30 | $1,102 |
| 2009-06-30 | $1,141 |
| 2009-03-31 | $1,080 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $10.939B | $14.739B |
| Viatris, Inc. is a global healthcare company. Its portfolio comprises more than thousand approved molecules across a wide range of key therapeutic areas, including globally recognized iconic and key brands, generic, complex generic, and biosimilar products. Branded products include EpiPen, Amitiza, Lipitor and Viagra. Biosimilars portfolio include pegfilgrastim, trastuzumab and adalimumab biosimilars. It has obtained approval for the biosimilar of Avastin and Insulin Aspart in Europe. The company reports in following segments: Developed Markets, Greater China, JANZ & Emerging Markets. The Developed Markets segment comprises operations in N. America and Europe. The Greater China segment operates in China, Taiwan and Hong Kong. The JANZ segment will report for operations in Japan, Australia and New Zealand, while the Emerging Markets segment will include operations in Asia, the Middle East, South and Central America, Africa and E. Europe. This segment also includes the company's anti-retroviral franchise. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Danaher (DHR) | United States | $145.424B | 27.27 |
| CVS Health (CVS) | United States | $85.300B | 10.60 |
| Elevance Health (ELV) | United States | $78.589B | 10.14 |
| Cencora (COR) | United States | $57.416B | 19.98 |
| DiDi Global (DIDIY) | China | $22.826B | 24.25 |
| Natera (NTRA) | United States | $22.088B | 0.00 |
| Labcorp Holdings (LH) | United States | $21.920B | 17.78 |
| BioMerieux (BMXMF) | France | $16.861B | 0.00 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $13.673B | 0.00 |
| Solventum (SOLV) | United States | $13.582B | 14.38 |
| CochLear (CHEOY) | Australia | $12.960B | 0.00 |
| ICON (ICLR) | Ireland | $12.122B | 11.27 |
| Revvity (RVTY) | United States | $11.941B | 20.55 |
| Avantor (AVTR) | United States | $9.458B | 13.74 |
| Medpace Holdings (MEDP) | United States | $9.240B | 24.54 |
| HealthEquity (HQY) | United States | $8.834B | 38.70 |
| Sonic Healthcare (SKHHY) | Australia | $8.518B | 0.00 |
| Charles River Laboratories (CRL) | United States | $7.717B | 15.12 |
| Caris Life Sciences,�Inc (CAI) | United States | $6.752B | 0.00 |
| Amplifon S.p.A (AMFPF) | Italy | $5.378B | 29.44 |
| Bausch + Lomb (BLCO) | Canada | $4.910B | 28.92 |
| BrightSpring Health Services (BTSG) | United States | $3.889B | 35.68 |
| Sotera Health (SHC) | United States | $3.334B | 18.94 |
| Surgery Partners (SGRY) | United States | $2.839B | 36.92 |
| Alignment Healthcare (ALHC) | United States | $2.685B | 0.00 |
| Concentras Parent (CON) | United States | $2.635B | 15.23 |
| GeneDx Holdings (WGS) | United States | $2.614B | 100.67 |
| Organon (OGN) | United States | $2.589B | 2.75 |
| PACS (PACS) | United States | $2.003B | 0.00 |
| Ardent Health (ARDT) | United States | $1.915B | 8.16 |
| Progyny (PGNY) | United States | $1.840B | 40.49 |
| Premier (PINC) | United States | $1.812B | 13.76 |
| GoodRx Holdings (GDRX) | United States | $1.682B | 33.64 |
| Teladoc Health (TDOC) | United States | $1.454B | 0.00 |
| Establishment Labs Holdings (ESTA) | $1.259B | 0.00 | |
| Pediatrix Medical (MD) | United States | $1.184B | 9.01 |
| CareDx (CDNA) | United States | $1.071B | 16.73 |
| Agilon Health (AGL) | United States | $1.006B | 0.00 |
| Ryman Healthcare (RYHTY) | New Zealand | $0.919B | 0.00 |
| AMN Healthcare Services Inc (AMN) | United States | $0.839B | 7.86 |
| QDM (QDMI) | Hong Kong, SAR China | $0.729B | 0.00 |
| Nutex Health (NUTX) | United States | $0.658B | 9.96 |
| Embecta (EMBC) | United States | $0.603B | 4.06 |
| InnovAge Holding (INNV) | United States | $0.602B | 0.00 |
| LifeMD (LFMD) | United States | $0.568B | 0.00 |
| Sonida Senior Living (SNDA) | United States | $0.481B | 0.00 |
| Omada Health (OMDA) | $0.480B | 0.00 | |
| Auna S.A (AUNA) | Luxembourg | $0.469B | 10.55 |
| SBC Medicals (SBC) | United States | $0.463B | 0.00 |
| Enhabit (EHAB) | United States | $0.387B | 31.88 |
| So-Young (SY) | China | $0.330B | 0.00 |
| Performant Healthcare (PHLT) | United States | $0.328B | 0.00 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.305B | 0.00 |
| Beauty Health (SKIN) | United States | $0.287B | 0.00 |
| Oncology Institute (TOI) | United States | $0.225B | 0.00 |
| DocGo (DCGO) | United States | $0.161B | 26.33 |
| Pheton Holdings (PTHL) | China | $0.126B | 0.00 |
| Sera Prognostics (SERA) | United States | $0.094B | 0.00 |
| KindlyMD (NAKA) | United States | $0.077B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.068B | 0.00 |
| NeueHealth (NEUE) | United States | $0.061B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.059B | 0.00 |
| ModivCare (MODV) | United States | $0.047B | 0.00 |
| Biodesix (BDSX) | United States | $0.040B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.035B | 0.00 |
| Basel Medical Group (BMGL) | Singapore | $0.032B | 0.00 |
| OSR Holdings (OSRH) | United States | $0.026B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.012B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.012B | 0.00 | |
| Co-Diagnostics (CODX) | United States | $0.009B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.006B | 0.00 |
| XWELL (XWEL) | United States | $0.005B | 0.00 |
| Aclarion (ACON) | United States | $0.004B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.004B | 0.00 |
| ISpecimen (ISPC) | United States | $0.002B | 0.00 |
| INVO Fertility (IVF) | United States | $0.002B | 0.00 |
| Cano Health (CANOQ) | United States | $0.000B | 0.00 |